These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25218783)

  • 1. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.
    van der Ree MH; van der Meer AJ; de Bruijne J; Maan R; van Vliet A; Welzel TM; Zeuzem S; Lawitz EJ; Rodriguez-Torres M; Kupcova V; Wiercinska-Drapalo A; Hodges MR; Janssen HL; Reesink HW
    Antiviral Res; 2014 Nov; 111():53-9. PubMed ID: 25218783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of HCV infection by targeting microRNA.
    Janssen HL; Reesink HW; Lawitz EJ; Zeuzem S; Rodriguez-Torres M; Patel K; van der Meer AJ; Patick AK; Chen A; Zhou Y; Persson R; King BD; Kauppinen S; Levin AA; Hodges MR
    N Engl J Med; 2013 May; 368(18):1685-94. PubMed ID: 23534542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma.
    van der Ree MH; van der Meer AJ; van Nuenen AC; de Bruijne J; Ottosen S; Janssen HL; Kootstra NA; Reesink HW
    Aliment Pharmacol Ther; 2016 Jan; 43(1):102-13. PubMed ID: 26503793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.
    Ottosen S; Parsley TB; Yang L; Zeh K; van Doorn LJ; van der Veer E; Raney AK; Hodges MR; Patick AK
    Antimicrob Agents Chemother; 2015 Jan; 59(1):599-608. PubMed ID: 25385103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection.
    Hsi E; Huang CF; Dai CY; Juo SH; Chou WW; Huang JF; Yeh ML; Lin ZY; Chen SC; Wang LY; Chuang WL; Yu ML
    Antiviral Res; 2014 May; 105():135-42. PubMed ID: 24637254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
    Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H
    J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
    Hara T; Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Kumada H
    J Med Virol; 2013 Oct; 85(10):1746-53. PubMed ID: 23861088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.
    van der Ree MH; de Vree JM; Stelma F; Willemse S; van der Valk M; Rietdijk S; Molenkamp R; Schinkel J; van Nuenen AC; Beuers U; Hadi S; Harbers M; van der Veer E; Liu K; Grundy J; Patick AK; Pavlicek A; Blem J; Huang M; Grint P; Neben S; Gibson NW; Kootstra NA; Reesink HW
    Lancet; 2017 Feb; 389(10070):709-717. PubMed ID: 28087069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.
    Ogata F; Kobayashi M; Akuta N; Osawa M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Suzuki F; Arase Y; Ikeda K; Kumada H
    Oncology; 2017; 93(2):92-98. PubMed ID: 28448999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation-A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion.
    Goldaracena N; Spetzler VN; Echeverri J; Kaths JM; Cherepanov V; Persson R; Hodges MR; Janssen HL; Selzner N; Grant DR; Feld JJ; Selzner M
    Am J Transplant; 2017 Apr; 17(4):970-978. PubMed ID: 27805315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection.
    Lee TH; Matta B; King BD; Hodges MR; Tillmann HL; Patel K
    J Med Virol; 2015 Oct; 87(10):1722-6. PubMed ID: 25963774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.
    Hyrina A; Olmstead AD; Steven P; Krajden M; Tam E; Jean F
    EBioMedicine; 2017 Sep; 23():68-78. PubMed ID: 28864162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4.
    Rossignol JF; Kabil SM; El-Gohary Y; Elfert A; Keeffe EB
    Aliment Pharmacol Ther; 2008 Sep; 28(5):574-80. PubMed ID: 18616643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3.
    Oliveira KG; Malta FM; Nastri AC; Widman A; Faria PL; Santana RA; Alves VA; Carrilho FJ; Pinho JR
    Med Microbiol Immunol; 2016 Apr; 205(2):111-7. PubMed ID: 26272127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.
    Lanford RE; Hildebrandt-Eriksen ES; Petri A; Persson R; Lindow M; Munk ME; Kauppinen S; Ørum H
    Science; 2010 Jan; 327(5962):198-201. PubMed ID: 19965718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV infection and miravirsen.
    Janssen HL; Kauppinen S; Hodges MR
    N Engl J Med; 2013 Aug; 369(9):878. PubMed ID: 23984739
    [No Abstract]   [Full Text] [Related]  

  • 18. HCV infection and miravirsen.
    Sanchez-Niño MD; Ortiz A
    N Engl J Med; 2013 Aug; 369(9):877-8. PubMed ID: 23984740
    [No Abstract]   [Full Text] [Related]  

  • 19. Functional analysis of microRNA-122 binding sequences of hepatitis C virus and identification of variants with high resistance against a specific antagomir.
    Li YP; Van Pham L; Uzcategui N; Bukh J
    J Gen Virol; 2016 Jun; 97(6):1381-1394. PubMed ID: 26935756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms involved in the development of chronic hepatitis C as potential targets of antiviral therapy.
    Jackowiak P; Figlerowicz M; Kurzyńska-Kokorniak A; Figlerowicz M
    Curr Pharm Biotechnol; 2011 Nov; 12(11):1774-80. PubMed ID: 21902631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.